Work

FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLNFGFR1): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated Patients

Year: 2022

Type: article

Source: Blood

DOI: 10.1182/blood-2022-163099

Authors: Srdan Verstovsek, Jason Gotlib, Alessandro M. Vannucchi, Alessandro Rambaldi, Andreas Reiter, William Shomali, Tracy I. George, Jay L. Patel, Philomena Colucci, Huiling Zhen, Natalia Oliveira, Jean-Jacques Kiladjian

Institutions: The University of Texas MD Anderson Cancer Center, Stanford Medicine, Stanford Cancer Institute, Stanford University, Azienda Ospedaliero-Universitaria Careggi, University of Milan, Ospedale Papa Giovanni XXIII, Heidelberg University, University Medical Centre Mannheim, University of Utah, ARUP Laboratories (United States), Incyte (United States), Hôpital Saint-Louis

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310160035

FWCI: 2.545

Cites:

Cited by: 14

Related to: 10